SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

NeoStem (NBS)

NBS RSS Feed
Add NBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator andy e
Search This Board:
Last Post: 5/30/2015 6:13:15 AM - Followers: 110 - Board type: Free - Posts Today: 2

NeoStem, Inc (NBS) 


 

 

 

http://www.neostem.com

 

 

 

 

Company Information:

420 Lexington Avenue
Suite 450

New York, New York 10170

Telephone: 212-584-4180
Fax: 646-514-7787

 

CIK:  0000320017

 

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and comprises a separate therapeutic technology platform in addition to the current three pillars of healthcare: pharmaceuticals, biologics and medical devices. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrow and organ transplantation, tissue banking and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others. We anticipate that cellular therapies will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
 
Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (“CDMO”) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
 
Progenitor Cell Therapy, LLC, our wholly owned subsidiary (“PCT”), is a leading CDMO in the cellular therapy industry. Since its inception in 1997, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services.
 
Our wholly-owned subsidiary, Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011, is developing our own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents our most clinically advanced therapeutic product candidate and enrollment for our Phase 2 PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (“AMI”) patients commenced in 2012. We expect to complete enrollment for this study in 2013 with the first data readout available six to eight months thereafter. If approved by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI, potentially improving the quality and longevity of life for those afflicted, and position the Company to capture a meaningful share of the worldwide AMI market.
 
Through our majority-owned subsidiary, Athelos Corporation (“Athelos”), we are collaborating with Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. We plan to investigate the clinical feasibility of nTreg-based therapeutics to prevent and/or treat type 1 diabetes, graft vs. host disease, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection and expect to file an Investigational New Drug Application ("IND") with the FDA in 2013 and commence human clinical studies in one of these disease conditions thereafter.
 
Our pre-clinical assets include our VSEL TM (Very Small Embryonic Like) Technology platform for which we expect to file an IND with the FDA in late 2013 or early 2014 to initiate an National Institutes of Health ("NIH") funded human clinical studies treating periodontitis with VSELs TM . We are also working on a Department of Defense funded study of VSELs TM and mesenchymal stem cells for the treatment of chronic wounds.
 
NeoStem's origins are in adult stem cell collection and storage and we believe that as new therapeutics are developed utilizing one's own stored cells (autologous), the market penetration rate for the collection and storage business may rise sharply from its current low single digits percentage level allowing our developing a network to scale rapidly if the demand grows.
 
We believe that NeoStem is ideally positioned to be an integrated leader in the cell therapy industry. We have significant basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise and a talented and experienced clinical team. We believe this expertise will allow us to achieve our mission of becoming the premier cell therapy company.

 




 

Management:   http://www.neostem.com/leadership/robin-l-smith.html

 

 

Feature Stories:   http://www.neostem.com/feature-stories/

 

 

Recent News:   http://www.neostem.com/media/

 

http://finance.yahoo.com/q/h?s=NBS+Headlines

 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000320017&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004

 


 

 

Investor Relations:

Robin L. Smith
Phone: +1 (212) 584-4174
email: rsmith@neostem.com


 

 

 

 

 

 

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
News News Alert: NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company 05/29/2015 08:26:19 AM
PostSubject
#1894   I actually love the format from a laptop F1ash 05/30/15 06:13:15 AM
#1893   I agree but the format here is terrible....not Lynx5100 05/30/15 03:00:52 AM
#1892   Just wanted to thank you for sharing your F1ash 05/29/15 11:47:31 AM
#1891   The shorting is there for certain, but days F1ash 05/29/15 10:28:25 AM
#1890   OMG I HOPE YOUR RIGHT!! lol Viperciara 05/29/15 10:27:08 AM
#1889   I agree, I have been trying to tell Viperciara 05/29/15 10:25:22 AM
#1888   I am in no way certain about what F1ash 05/29/15 10:23:34 AM
#1887   A decisive treatment for cancer is worth $60 InvestorStemCell 05/29/15 10:19:24 AM
#1886   Caladrius Bioscience fits!! Viperciara 05/29/15 08:43:21 AM
#1885   NeoStem Announces Plans to Change Name to Caladrius Viperciara 05/29/15 08:34:22 AM
#1884   Nice to see intelligent posted here! Lynx5100 05/29/15 07:28:15 AM
#1883   California Stem Cell Report Viperciara 05/29/15 06:32:34 AM
#1882   I agree with you. This company is worth Viperciara 05/29/15 05:37:30 AM
#1881   A clinical research study to test a new Viperciara 05/29/15 05:26:57 AM
#1880   Fighting cancer with innovative immunotherapy techniques Viperciara 05/29/15 05:16:34 AM
#1879   I agree the company is worth a lot! Viperciara 05/29/15 05:11:40 AM
#1878   Agree great bargsin low entry time and lots brando5 05/29/15 04:28:49 AM
#1877   What a gift to have gotten in today. Seventeenseconds 05/28/15 09:54:57 PM
#1876   Just a few weeks ago; MLV & Co. initiated James salmon 05/28/15 07:09:45 PM
#1875   Neostem (NBS) Stock Declines After Pricing Secondary Public Offering Viperciara 05/28/15 06:46:31 PM
#1874   MidPoint / David Mazzo discusses melanoma skin cancer Viperciara 05/28/15 06:27:26 PM
#1873   This company is worth over $2 a share brando5 05/28/15 06:23:08 PM
#1872   Excellent discount price right now. This is,a solid brando5 05/28/15 06:19:35 PM
#1871   Deal doesn't close until June 2 and then brando5 05/28/15 06:17:27 PM
#1870   So the IPO is underwritten for $25 milly shrewdop 05/28/15 04:08:07 PM
#1869   I will see what the shorts do now. InvestorStemCell 05/28/15 10:44:56 AM
#1868   Yes it can be a tough cruel battle brando5 05/28/15 09:12:05 AM
#1867   I agree with you that these are bargain duderaja 05/28/15 09:07:01 AM
#1866   I've been in several bio's and most all duderaja 05/28/15 08:35:10 AM
#1865   I just bought more at $2 lol. I brando5 05/28/15 08:17:05 AM
#1864   I totally agree with what you are saying, Viperciara 05/28/15 08:12:51 AM
#1863   Well if goes to $2 I'll accumulate. I brando5 05/28/15 08:02:58 AM
#1862   I bought 20K shares yesterday for a loss Viperciara 05/28/15 08:02:30 AM
#1861   I feel your pain Viper. I know duderaja 05/28/15 07:43:57 AM
#1860   Brando5 you do realize the analyst price was Viperciara 05/28/15 07:16:34 AM
#1859   The underwriter bought for $2 a share doesn't brando5 05/28/15 04:48:17 AM
#1858   Agree. Patience. This will move NBS forward and brando5 05/28/15 01:44:50 AM
#1857   I'm new here but would like to offer F1ash 05/27/15 11:35:27 PM
#1856   Only matters what I know. brando5 05/27/15 08:02:36 PM
#1855   LOL....all conjecture! andy e 05/27/15 07:55:47 PM
#1854   Totally agree Viper...just goes to show companies will andy e 05/27/15 07:53:34 PM
#1853   Oops. Based on that of other professional opinions brando5 05/27/15 07:52:12 PM
#1852   Maybe just my opinion. brando5 05/27/15 07:51:38 PM
#1851   Think this will go to $2? brando5 05/27/15 07:51:15 PM
#1850   That whole post is still just your opinion. andy e 05/27/15 07:48:42 PM
#1849   Drug will be out by 2018. Big things brando5 05/27/15 07:41:59 PM
#1848   He needs to makeup for this. To help brando5 05/27/15 07:40:24 PM
#1847   Big things here and yes NBS has huge brando5 05/27/15 07:37:05 PM
#1846   A lot has happened in 3 years! They brando5 05/27/15 07:33:30 PM
#1845   You do realize Phase 3 will end in Viperciara 05/27/15 07:28:30 PM
PostSubject